Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00141141 |
The purpose of this study is to evaluate the efficacy of Atorvastin vs Simvastatin in decreasing LDL-C in diabetic subjects with hypercholesterolemia at the end of the treatment phase.
Condition | Intervention | Phase |
---|---|---|
Hypercholesterolemia |
Drug: Atorvastatin Drug: Simvastatin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase IV, Multicenter, Randomized, Open Label Study To Evaluate The Efficacy And Safety Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia |
Enrollment: | 383 |
Study Start Date: | January 2004 |
Study Completion Date: | April 2007 |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Italy | |
Pfizer Investigational Site | |
CAMPOBASSO, Italy, 86100 | |
Pfizer Investigational Site | |
GENOVA, Italy, 16132 | |
Pfizer Investigational Site | |
PERUGIA, Italy, 06100 | |
Pfizer Investigational Site | |
PISA, Italy, 56124 | |
Pfizer Investigational Site | |
ROMA, Italy, 00161 | |
Pfizer Investigational Site | |
ANCONA, Italy, 60100 | |
Pfizer Investigational Site | |
ASTI, Italy, 14100 | |
Pfizer Investigational Site | |
ROMA, Italy, 00168 | |
Pfizer Investigational Site | |
BARI, Italy, 70124 | |
Pfizer Investigational Site | |
CATANZARO, Italy, 88100 | |
Pfizer Investigational Site | |
UDINE, Italy, 33100 | |
Pfizer Investigational Site | |
PALERMO, Italy, 90127 | |
Pfizer Investigational Site | |
NAPOLI, Italy, 80100 | |
Pfizer Investigational Site | |
RIMINI, Italy, 47900 | |
Pfizer Investigational Site | |
CAGLIARI, Italy, 09134 | |
Pfizer Investigational Site | |
MILANO, Italy, 20142 | |
Pfizer Investigational Site | |
ROMA, Italy, 00155 | |
Pfizer Investigational Site | |
MILANO, Italy, 20145 | |
Pfizer Investigational Site | |
TORINO, Italy, 10154 | |
Pfizer Investigational Site | |
MESSINA, Italy, 98158 | |
Pfizer Investigational Site | |
NAPOLI, Italy, 80131 | |
Pfizer Investigational Site | |
CATANIA, Italy, 95124 | |
Pfizer Investigational Site | |
S. Benedetto del Tronto (AP), Italy, 63039 | |
Pfizer Investigational Site | |
CATANIA, Italy, 95126 | |
Pfizer Investigational Site | |
PARMA, Italy, 43100 | |
Pfizer Investigational Site | |
Roma, Italy, 00161 | |
Pfizer Investigational Site | |
POTENZA, Italy, 85100 | |
Pfizer Investigational Site | |
Milano, Italy, 20157 | |
Pfizer Investigational Site | |
Ferrara, Italy, 44100 | |
Pfizer Investigational Site | |
Roma, Italy, 00163 | |
Italy, Ascoli Piceno | |
Pfizer Investigational Site | |
S. BENEDETTO DEL TRONTO, Ascoli Piceno, Italy, 63039 | |
Italy, Brindisi | |
Pfizer Investigational Site | |
S.Pietro Vernotico, Brindisi, Italy | |
Italy, LECCE | |
Pfizer Investigational Site | |
CASARANO, LECCE, Italy, 73043 | |
Italy, PV | |
Pfizer Investigational Site | |
PAVIA, PV, Italy, 27100 | |
Italy, TORINO | |
Pfizer Investigational Site | |
ORBASSANO, TORINO, Italy, 10043 | |
Italy, VE | |
Pfizer Investigational Site | |
MESTRE, VE, Italy, 30174 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A2581053 |
Study First Received: | August 30, 2005 |
Last Updated: | October 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00141141 |
Health Authority: | Italy: Ministry of Health |
Metabolic Diseases Hyperlipidemias Simvastatin Metabolic disorder |
Hypercholesterolemia Atorvastatin Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |